Document 0702
 DOCN  M9440702
 TI    Inhibitors of HIV-1 protease.
 DT    9404
 AU    Meek TD; Department of Medicinal Chemistry, SmithKline Beecham;
       Pharmaceuticals, King of Prussia, Pennsylvania 19406.
 SO    J Enzym Inhib. 1992;6(1):65-98. Unique Identifier : AIDSLINE
       MED/94132924
 AB    The human immunodeficiency virus (HIV), the etiological agent for the
       acquired immune deficiency syndrome (AIDS), is a retrovirus which makes
       use of a virally-encoded aspartic protease to perform specific
       proteolytic processing of two of its gene products in order to form
       active enzymes and structural proteins within the mature virion.
       Accordingly, specific, exogenous inhibition of the HIV-1 protease is
       thought to be a viable approach for the development of novel
       therapeutics for the treatment of AIDS. Indeed, this hypothesis has been
       validated in virally-infected cell culture with synthetic inhibitors of
       HIV-1 protease. This chapter reviews the current status of the
       development of inhibitors of this enzyme.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Amino Acid Sequence
       Antiviral Agents/*PHARMACOLOGY/THERAPEUTIC USE  HIV Protease/*METABOLISM
       HIV Protease Inhibitors/*PHARMACOLOGY/THERAPEUTIC USE  HIV-1/DRUG
       EFFECTS/*ENZYMOLOGY/GROWTH & DEVELOPMENT  Molecular Conformation
       Molecular Sequence Data  Substrate Specificity  Virus Replication
       JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).